Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number...
Main Authors: | Mitchell, R, Trück, J, Pollard, A |
---|---|
Format: | Journal article |
Sprog: | English |
Udgivet: |
2013
|
Lignende værker
-
The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
af: Trück, J, et al.
Udgivet: (2016) -
Differences in immunization site pain in toddlers vaccinated with either the 10- or the 13-valent pneumococcal conjugate vaccine
af: Trück, J, et al.
Udgivet: (2018) -
13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
af: V. K. Tatochenko, et al.
Udgivet: (2012-03-01) -
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
af: James T. Peterson, et al.
Udgivet: (2019-03-01) -
13-valent pneumococcal conjugate vaccine in Africa
af: Robert Cohen, et al.
Udgivet: (2017-03-01)